These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 34176383)

  • 1. A medicine adoption model for assessing the expected effects of additional real-world evidence (RWE) at product launch.
    Jandhyala R
    Curr Med Res Opin; 2021 Sep; 37(9):1645-1655. PubMed ID: 34176383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The multiple stakeholder approach to real-world evidence (RWE) generation: observing multidisciplinary expert consensus on quality indicators of rare disease patient registries (RDRs).
    Jandhyala R
    Curr Med Res Opin; 2021 Jul; 37(7):1249-1257. PubMed ID: 33989087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of adding real-world evidence to regulatory submissions on the breadth of population indicated for rare disease medicine treatment by the European Medicines Agency.
    Jandhyala R
    J Pharm Policy Pract; 2022 May; 15(1):36. PubMed ID: 35509059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Observing expert opinion of medical affairs pharmaceutical physicians on the value of their clinical experience to the pharmaceutical industry using the Jandhyala method.
    Jandhyala R; Rout R
    Curr Med Res Opin; 2023 Dec; 39(12):1541-1550. PubMed ID: 36632732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Commercial impact of adding real-world evidence to clinical trials at regulatory approval: a Markovian-like transition model.
    Jandhyala R
    Curr Med Res Opin; 2023 Dec; 39(12):1559-1566. PubMed ID: 36715502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a definition for real-world evidence using the Jandhyala method for observing consensus opinion among medical affairs pharmaceutical physicians.
    Jandhyala R
    Curr Med Res Opin; 2023 Dec; 39(12):1551-1558. PubMed ID: 36710630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real world evidence (RWE) - a disruptive innovation or the quiet evolution of medical evidence generation?
    Khosla S; White R; Medina J; Ouwens M; Emmas C; Koder T; Male G; Leonard S
    F1000Res; 2018; 7():111. PubMed ID: 30026923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world evidence: perspectives on challenges, value, and alignment of regulatory and national health technology assessment data collection requirements.
    Sievers H; Joos A; Hiligsmann M
    Int J Technol Assess Health Care; 2021 Feb; 37():e40. PubMed ID: 33622423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a Definition for Medical Affairs Using the Jandhyala Method for Observing Consensus Opinion Among Medical Affairs Pharmaceutical Physicians.
    Jandhyala R
    Front Pharmacol; 2022; 13():842431. PubMed ID: 35273511
    [No Abstract]   [Full Text] [Related]  

  • 10. Development and Validation of the Medical Affairs Pharmaceutical Physician Value (MAPPval) Instrument.
    Jandhyala R
    Pharmaceut Med; 2022 Feb; 36(1):47-57. PubMed ID: 34994965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advancing the use of real world evidence in health technology assessment: insights from a multi-stakeholder workshop.
    Claire R; Elvidge J; Hanif S; Goovaerts H; Rijnbeek PR; Jónsson P; Facey K; Dawoud D
    Front Pharmacol; 2023; 14():1289365. PubMed ID: 38283835
    [No Abstract]   [Full Text] [Related]  

  • 12. Use of real-world evidence for oncology clinical decision making in emerging economies.
    Petracci F; Ghai C; Pangilinan A; Suarez LA; Uehara R; Ghosn M
    Future Oncol; 2021 Aug; 17(22):2951-2960. PubMed ID: 34044583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of real-world evidence in cancer drug funding decisions in Canada: a qualitative study of stakeholders' perspectives.
    Clausen M; Mighton C; Kiflen R; Sebastian A; Dai WF; Mercer RE; Beca JM; Isaranuwatchai W; Chan KKW; Bombard Y
    CMAJ Open; 2020; 8(4):E772-E778. PubMed ID: 33234584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Translational hurdles with cannabis medicines.
    Graham M; Lucas CJ; Schneider J; Martin JH; Hall W
    Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1325-1330. PubMed ID: 32281186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of real-world data and evidence for medical devices: a qualitative study of key informant interviews.
    Polisena J; Jayaraman G
    Int J Technol Assess Health Care; 2020 Dec; 36(6):579-584. PubMed ID: 33161916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing-Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative.
    Orsini LS; Berger M; Crown W; Daniel G; Eichler HG; Goettsch W; Graff J; Guerino J; Jonsson P; Lederer NM; Monz B; Mullins CD; Schneeweiss S; Brunt DV; Wang SV; Willke RJ
    Value Health; 2020 Sep; 23(9):1128-1136. PubMed ID: 32940229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The utility of real-world evidence for benefit-risk assessment, communication, and evaluation of pharmaceuticals: Case studies.
    Radawski CA; Hammad TA; Colilla S; Coplan P; Hornbuckle K; Freeman E; Smith MY; Sobel RE; Bahri P; Arias AE; Bennett D
    Pharmacoepidemiol Drug Saf; 2020 Dec; 29(12):1532-1539. PubMed ID: 33146901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving transparency to build trust in real-world secondary data studies for hypothesis testing-Why, what, and how: recommendations and a road map from the real-world evidence transparency initiative.
    Orsini LS; Monz B; Mullins CD; Van Brunt D; Daniel G; Eichler HG; Graff J; Guerino J; Berger M; Lederer NM; Jonsson P; Schneeweiss S; Wang SV; Crown W; Goettsch W; Willke RJ
    Pharmacoepidemiol Drug Saf; 2020 Nov; 29(11):1504-1513. PubMed ID: 32924243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Real-World Evidence for Regulatory Approval and Coverage of Medical Devices: A Landscape Assessment.
    Timbie JW; Kim AY; Concannon TW
    Value Health; 2021 Dec; 24(12):1792-1798. PubMed ID: 34838277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-Community Perspectives on Real-World Evidence: Enhancing Engagement, Understanding, and Trust.
    Oehrlein EM; Graff JS; Harris J; Perfetto EM
    Patient; 2019 Aug; 12(4):375-381. PubMed ID: 30666526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.